Nerve Growth Factor ( DrugBank: Nerve Growth Factor )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 3 | Spinal muscular atrophy | 1 |
| 53 | Sjogren syndrome | 1 |
| 90 | Retinitis pigmentosa | 2 |
3. Spinal muscular atrophy
Clinical trials : 237 / Drugs : 123 - (DrugBank : 29) / Drug target genes : 51 - Drug target pathways : 75
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR-TRC-10001093 | 2010-10-01 | 2010-11-02 | Rat nerve growth factor injection in the treatment of children with spinal muscular atrophy: a randomized controlled trial | Rat nerve growth factor injection in the treatment of children with spinal muscular atrophy: a randomized controlled trial | children with spinal muscular atrophy | A:Rat nerve growth factor injection for six monthes,;B:Rat nerve growth factor injection for six monthes,; | PLA General Hospital | NULL | Completed | 3 | 8 | Both | A:20;B:20; | China |
53. Sjogren syndrome
Clinical trials : 305 / Drugs : 325 - (DrugBank : 104) / Drug target genes : 58 - Drug target pathways : 188
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2021-003749-39-IT (EUCTR) | 15/12/2021 | 15/10/2021 | A 4 week, Phase III, multicenter, double-masked, study to evaluate safety and efficacy of Oxervate® (cenegermin) 20 mcg/mL ophthalmic solution in patients with severe Sjogren’s dry eye disease under treatment with Cyclosporine A. | A 4 week, Phase III, multicenter, double-masked, vehicle-controlled study to evaluate safety and efficacy of Cenegermin (Oxervate®) 20 mcg/mL ophthalmic solution versus vehicle, in patients with severe Sjogren’s dry eye disease under treatment with Cyclosporine A. - NGF0221 | Severe Sjogren’s dry eye disease MedDRA version: 21.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Trade Name: Oxervate Product Name: OXERVATE Product Code: [Recombinant Human Nerve Growth Factor (rhNGF)] INN or Proposed INN: Cenegermin Other descriptive name: Recombinant form of human nerve growth factor produced in Escherichia Coli. | DOMPé FARMACEUTICI S.P.A. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 48 | Phase 3 | United States;Italy |
90. Retinitis pigmentosa
Clinical trials : 147 / Drugs : 176 - (DrugBank : 43) / Drug target genes : 49 - Drug target pathways : 110
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02609165 (ClinicalTrials.gov) | May 2015 | 12/10/2015 | Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema | Nerve Growth Factor Eye Drops as a Novel Treatment for Vision Loss in Patients With Retinitis Pigmentosa: From Preclinical to Clinical Phase II Trial | Retinitis Pigmentosa;Cystoid Macular Edema | Drug: rhNGF 180 µg/ml eye drops solution;Drug: vehicle eye drops | Ospedale San Raffaele | Dompé Farmaceutici S.p.A | Completed | 18 Years | N/A | All | 45 | Phase 2 | Italy |
| 2 | EUCTR2014-000385-22-IT (EUCTR) | 07/10/2014 | 12/05/2014 | Nerve Growth Factor eye drops as a novel treatment for patients with Retinitis Pigmentosa. | Nerve Growth Factor eye drops as a novel treatment for vision loss in patients with Retinitis Pigmentosa: from preclinical toclinical Phase II trial. - NEMO | Retinitis pigmentosa with cystoid macular edema MedDRA version: 17.0;Level: LLT;Classification code 10054467;Term: Macular edema;System Organ Class: 100000004853 MedDRA version: 17.0;Level: PT;Classification code 10038914;Term: Retinitis pigmentosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Product Name: recombinant human Nerve Growth Factor (rhNGF) INN or Proposed INN: not yet assigned Other descriptive name: RECOMBINANT HUMAN NERVE GROWTH FACTOR (RHNGF) | Ospedale San Raffaele di Milano | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Phase 2 | Italy |